Acquisitions: #Ancestry > #iMemories; #Darktrace > #MiraSecurity; #EliLilly > #VerveTherapeutics; #IntegratedDiagnosticServices > #CommunityofNevedaDiagnostics; #Ironmark > #AmericanMarketing&MailingServices; #NiCE > #Cognigy; #SuperiorEnvironmentalSolutions > #Hydroblasters

Click Subscribe #Investing #StockMarket #VerveTherapeutics #BMOCapitalMarkets #EliLilly

2) .. belirli şartların gerçekleşmesi durumunda ek olarak hisse başına 3 dolara kadar ödeme yapılabilecek. Tek dozla kalıcı kardiyovasküler risk azaltımı hedefleyen Verve’in satın alımı, 2025’in üçüncü çeyreğinde tamamlanacak. #fortuneturkey #elililly #vervetherapeutics

Stocks to Watch Recap: T-Mobile, Eli Lilly, Verve Therapeutics, First Solar - WSJ Stocks to Watch Recap: T-Mobile, Eli Lilly, Verve Therapeutics, First Solar  WSJ

Click Subscribe #Stocks #TMobile #EliLilly #VerveTherapeutics #FirstSolar

Stocks to Watch Recap: T-Mobile, Eli Lilly, Verve Therapeutics, First Solar - WSJ Stocks to Watch Recap: T-Mobile, Eli Lilly, Verve Therapeutics, First Solar  WSJ

Click Subscribe #Stocks #Investing #TMobile #EliLilly #VerveTherapeutics

#trends today for 'aew star' 'fire extinguisher' & 'verve therapeutics'

Click/Tap below:

www.newsmason.com?query=%22aew...

www.newsmason.com?query=%22fir...

www.newsmason.com?query=%22ver...

#aewstar #fireextinguisher #vervetherapeutics

Eli Lilly to acquire gene-editing therapy developer Verve Therapeutics for up to $1.3 billion, companies say Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

Click Subscribe #EliLilly #VerveTherapeutics #GeneEditing #Pharmaceuticals #InvestmentNews

#VerveTherapeutics CEO did what was best for the medicine, but also good for shareholders.

Though Eli Lilly will get to buy them for too cheap, investors can reinvest quickly into $NTLA $PRME and maybe $MGX for hopefully another easy double. #CRISPR

Eli Lilly nears $1.3 billion deal for gene-editing biotech Verve Therapeutics, FT reports (Reuters) -Eli Lilly is in advanced talks to acquire gene editing startup Verve Therapeutics for up to $1.3 billion, aiming to strengthen its pipeline of experimental medicines, the Financial Times reported on Monday. The drug maker’s acquisition bid includes a payment of almost $1 billion upfront for Verve, and a further $300 million based on the genetic medicines company achieving certain clinical milestones, the report said, citing people familiar with the matter. The deal could be announced as early as this week, provided talks stay on track, the report added. Eli Lilly (NYSE:LLY) declined to comment, while Verve Therapeutics did not immediately respond to a Reuters request for comment outside regular business hours.

Click Subscribe #EliLilly #Biotech #GeneEditing #VerveTherapeutics #InvestmentNews

Eli Lilly close to buying gene editing firm Verve for $1.3 bln- FT Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

Click Subscribe #EliLilly #VerveTherapeutics #GeneEditing #PharmaNews #BioTech

What we've learned since #IntelliaTherapeutics liver enzyme disclosure 2 weeks ago:

1) late response (week 4-5)...unlikely LNP tox
2) VERVE-102 uses same ionizable lipid as NTLA-2001/2 (from Novartis)
3) no clinical halts 2 weeks after event #VerveTherapeutics #CRISPR

#VerveTherapeutics and #PrimeMedicine should exchange clinically proven GalNAc-LNP and prime editing rights. Win-win. No need to take undue delivery safety risk here, and #Verve paid too much to #Beam for #CRISPR access.

#ANGPTL3 it may be time for #ArrowheadTherapeutics and #VerveTherapeutics to reposition their ANGPTL3-targeting agents from currently only homoFH and potentially ASCVD...to much larger #MASH opportunity.

See also #EliLilly's solbinsiran and Arrowhead's zodasiran ANGPTL3 results:

#VerveTherapeutics the oral #PCSK9 AZD0780 discussion part sets out by stating that only 10-30% (!) reach LDLc goal.

Yeah right, adding a 10th daily oral LDLc option will change that:

#VerveTherapeutics update on ongoing 0.7mg/kg high-dose cohort in #VERVE-102 PCSK9 study from CEO: safety so far so good. Have to see if can get efficacy from reliable -50% LDLc to -55 to -60% range. #exciting

Verve Therapeutics Announces Pipeline Progress and Reports First Quarter 2025 Financial Results Reported positive initial data from the Heart-2 Phase 1b clinical trial of VERVE-102 demonstrating dose-dependent decreases in blood LDL-C and PCSK9 Mean reduction in LDL-C of 53%, with a maximum redu...

#VerveTherapeutics full steam ahead:

- full p1 PCSK9 data, Lilly opt-in decision, p2 start in H2

- first ANGPTL3 clinical data in H2; they'll solve homoFH with the GalNac LNPs

- Lpa advancing towards clinic with Lilly still on board (Q1 milestone)

finance.yahoo.com/news/verve-t...

#VERVE-102 Multiple risks with upcoming data read-out.

Safety may be OK based on recent comms.
The other is #efficacy. In NHPs they used 5x the top dose in the clinical trial to achieve (solid) 62% LDLc reduction with GalNAc-LNP. If LDLc reduction is <40%, #VerveTherapeutics is toast.

Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) by the United States (U.S.) Food and Drug Administ... U.S. IND Represents Regulatory Clearance For BEAM-302 Spanning Six Countries and Second Open IND for a Beam In Vivo Base Editing Program in the U.S. CAMBRIDGE, Mass., March 27, 2025 (GLOBE NEWSWIRE) -...

Following on the heels of #VerveTherapeutics with VERVE-102, #BeamTherapeutics also got IND clearance from FDA for its #BaseEditing therapeutic: finance.yahoo.com/news/beam-th...